Ones To Watch News
Refine Search
Biotechnology
UK privately-held T-regulatory (Treg) cell therapies developer Quell Therapeutics today revealed that pharma major AstraZeneca has selected a lead Treg cell therapy candidate to progress from the inflammatory bowel disease (IBD) program. 10 June 2025
Pharmaceutical
UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO). 10 June 2025
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly 11% higher. 10 June 2025
Biosimilars
Specialty immunotherapy company Tevogen Bio Holdings has announced the execution of a lease agreement to expand its corporate headquarters in Warren, New Jersey, more than doubling its footprint. 10 June 2025
Biotechnology
Swiss pharma company Idorsia today announced the appointment of Dr Srishti Gupta as chief executive (CEO), effective July 1, 2025. 10 June 2025
Biotechnology
Dutch late-stage biotech NewAmsterdam Pharma late yesterday announced positive top-line data from prespecified Alzheimer’s disease (AD) biomarker analyses in the Phase III BROADWAY clinical trial (NCT05142722). The firm’s US-traded shares were up 4.1% at $20.99 in pre-market activity this morning. 10 June 2025
Biotechnology
Shares of USA-based Elevation Oncology leapt more than 20% to $0.38, on the news that it has accepted a takeover bid from Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, an investment firm focused on buying struggling biotechs and shutting them down. 10 June 2025
Biotechnology
US ophthalmic gene therapy company Beacon Therapeutics, which is focused on restoring the vision of patients with blinding retinal diseases, has appointed Daniel Chung as chief medical officer (CMO). 9 June 2025
Biotechnology
France-based SparingVision, a genomic medicine company focused on the treatment of retinal disease, has announced the appointment of Kalliopi ‘Kali’ Stasi, as chief medical officer, effective immediately. 9 June 2025
Biotechnology
Shares of Avidity Biosciences were up almost 5% at $38.00 pre-market today, as it announced the accelerated approval regulatory pathway in the USA is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (FSHD). 9 June 2025
Pharmaceutical
George Medicines, a late-stage UK-based biopharmaceutical company focused on addressing unmet needs in cardiometabolic disease, revealed a regulatory approval that it says could reshape hypertension treatment in the USA. 9 June 2025
Pharmaceutical
Canada-based Knight Therapeutics and the US subsidiary of Japan’s Sumitomo Pharma have entered into exclusive license and supply agreements to commercialize certain products. 9 June 2025
Biotechnology
Texas-based ImmunoPrecise Antibodies, a leader in AI-driven biotherapeutics, closed 22% higher Thursday. 6 June 2025
Biotechnology
US commercial-stage drugmaker Corcept Therapeutics has presented results from its DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) 2025 annual meeting. 6 June 2025
Biotechnology
US gene therapy company RegeNXBio yesterday announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, RegeNXBio’s potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy. 6 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Biotechnology
German genetic medicine company ViGeneron has announced a rebrand to become VeonGen Therapeutics. 5 June 2025
Pharmaceutical
US biotech BioAge Labs is expanding its obesity pipeline just months after shelving its lead drug in the category due to liver toxicity. 4 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
US pharma major Eli Lilly has struck a deal worth up to $870 million with Swedish biotech Camurus, securing global rights to apply the latter’s extended-release delivery platform to a set of its own metabolic disease compounds. 4 June 2025
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
French biotechnology company MaaT Pharma remains at the forefront of microbiome-based therapies, with new data on MaaT013 showing strong potential in acute graft-versus-host disease (aGvHD). 10 December 2024
Pharmaceutical
Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. 9 December 2024
Biotechnology
Dutch biotech Citryll, which is focused on treating immune-mediated inflammatory diseases by targeting neutrophil extracellular traps (NETs), today announced the successful closing of an oversubscribed 85 million euros ($89.8 million) Series B fundraise. 9 December 2024
Biotechnology
Leading early-stage biotech investor Atlas Ventures has closed its fourteenth fund with $450 million in an oversubscribed raise. 6 December 2024
Biotechnology
Ophthalmic gene therapy company Beacon Therapeutics Holdings has announced the presentation of three-month interim safety and efficacy results of AGTC-501 (laruparetigene zovaparvovec; laru-zova) in the Phase II DAWN trial in patients with X-linked retinitis pigmentosa (XLRP at the FLORetina-ICOOR Meeting 2024 in Florence, Italy. 6 December 2024
Biotechnology
Menlo Park-based Nuvig Therapeutics has raised $161 million in a series B financing round co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners. 6 December 2024
Biotechnology
Privately-held Muna Therapeutics, a Danish biotech focused on neurodegenerative diseases, has announced a research alliance with UK pharma major GSK to identify and validate novel drug targets for the treatment of Alzheimer’s disease. 5 December 2024
Biotechnology
Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ublituximab (150mg concentrate for solution for infusion) in the treatment of relapsing-remitting multiple sclerosis (RRMS). 5 December 2024
Biotechnology
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Bizengri (zenocutuzumab-zbco; Zeno) from Dutch firm Merus NV, whose shares edged up 1.8% to $46.32 on the news. 5 December 2024
Biotechnology
Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules targeting RNA for oncology and neurological disorders, announced today that it has entered into a multi-year, multi-target strategic research alliance with the UK’s GSK. 4 December 2024
Biotechnology
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal for its lirafugratinib. 4 December 2024
Biotechnology
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, has entered into a strategic research collaboration with Japan’s Mitsubishi Tanabe Pharma Corporation (MTPC). 4 December 2024
Biotechnology
Chinese biotech Duality Biologics yesterday revealed that it has entered into an exclusive option agreement with UK pharma major GSK for a potentially best-in-class ADC candidate, DB-1324. 4 December 2024
Biotechnology
Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb. 4 December 2024
Biotechnology
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has entered into a drug discovery collaboration agreement with privately-held Canadian firm Congruence Therapeutics. 4 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
Danish drug developer Antag Therapeutics, which is pioneering novel treatments for obesity, today announced the closing of an 80 million euros ($83.8 million) Series A financing. 4 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze